Findings

What do systematic reviews say?

23 questions · 26 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 42.3%GRADE not reported 0 · 0%Very low 8 · 30.8%Low 2 · 7.7%Moderate 5 · 19.2%High 0 · 0%

Short‐acting inhaled beta‐2 agonists vs placebo

Adverse events Â · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events Â compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 47 participants
Very low

Short‐acting inhaled beta‐2 agonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 100 participants
Very low

Short‐acting inhaled beta‐2 agonists vs placebo

Sputum: volume · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes sputum volume (mL) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low